This story has been updated to clarify GnuBio's commercialization plans.

One week after GnuBio announced that it had expanded into an 11,000-square-foot space as it prepares to enter commercialization, it is already reaching capacity, CEO John Boyce told In Sequence.

The company, which is developing a $50,000 microfluidic sequencer, has nearly doubled its employees over the last year to around 28 and expects to double in size again by the end of next year, Boyce said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.